PALANDRI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 773
EU - Europa 470
AS - Asia 134
AF - Africa 10
Totale 1.387
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 771
RU - Federazione Russa 266
IE - Irlanda 58
SE - Svezia 55
HK - Hong Kong 51
IT - Italia 46
CN - Cina 36
SG - Singapore 27
DE - Germania 10
CH - Svizzera 9
CI - Costa d'Avorio 9
IN - India 8
JO - Giordania 8
FI - Finlandia 7
GB - Regno Unito 7
CZ - Repubblica Ceca 5
UA - Ucraina 5
TR - Turchia 4
CA - Canada 1
DK - Danimarca 1
MX - Messico 1
RO - Romania 1
SC - Seychelles 1
Totale 1.387
Salva come PNG Salva come JPEG
Città #
Santa Clara 329
Chandler 78
Dublin 58
Ashburn 51
Hong Kong 34
Altamura 24
Lawrence 24
Moscow 19
Singapore 19
Fairfield 18
Princeton 14
Shanghai 13
Beijing 12
Cambridge 12
Seattle 12
Boston 11
Wilmington 10
Abidjan 9
Bern 9
Jacksonville 9
San Diego 9
Woodbridge 9
Boardman 8
Medford 8
Mumbai 8
Washington 8
Buffalo 7
Houston 7
Prague 5
Andover 4
Izmir 4
Ann Arbor 3
Bremen 3
Brugherio 3
London 3
Hangzhou 2
Helsinki 2
Kent 2
Lappeenranta 2
Norwalk 2
Pistoia 2
Rome 2
San Mateo 2
Arnsberg 1
Chicago 1
Falls Church 1
Florence 1
Fontevivo 1
Foshan 1
Genoa 1
Hillsboro 1
Hvidovre 1
New Bedfont 1
Redmond 1
Reston 1
Shenzhen 1
Springfield 1
Toronto 1
Treviso 1
Trumbull 1
West Jordan 1
Yubileyny 1
Totale 889
Salva come PNG Salva come JPEG
Nome #
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 107
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 94
A modified adenine chemically coupled to the allergen molecule of Dermatophagoides pteronyssinus redirects allergen-specific Th2 cells 91
Total serum IgE levels influence the in vitro detection of ss-lactams-specific IgE antibodies 86
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 77
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients 77
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey 74
A modified adenine chemically coupled to allergen molecule(s) induce Interferon-gamma production and down regulate IL-4 and IL-5 in Th2 specific T cells 73
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 72
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis 71
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study 70
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 70
Long-term follow-up of recovered MPN patients with COVID-19 64
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 63
MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study 50
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis 48
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT 47
Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis 46
Incidence of blast phase in myelofibrosis according to anemia severity 42
Breakthrough infections in MPN-COVID vaccinated patients 40
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options 30
null 15
Totale 1.407
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.422
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.422
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202046 0 0 0 0 5 5 4 8 5 7 7 5
2020/202147 3 2 4 3 3 5 0 10 4 6 4 3
2021/202278 3 1 3 1 0 3 0 23 3 1 10 30
2022/2023319 24 73 20 17 23 45 32 21 38 6 8 12
2023/2024201 5 14 25 18 21 32 7 44 3 14 3 15
2024/2025698 19 85 66 149 379 0 0 0 0 0 0 0
Totale 1.407